Phase 1 Trial of D2C7-IT in Combination With 2141-V11 for Recurrent Malignant Glioma

This early-phase study is testing two experimental treatments injected directly into the brain tumor — D2C7-IT (a targeted toxin) and 2141-V11 (an immune-activating antibody) — for patients with high-grade brain tumors (malignant glioma) that have come back after initial treatment. **You may be eligible if...** - You are 18 or older with a confirmed diagnosis of a recurrent high-grade (grade 3 or 4) brain tumor (malignant glioma or glioblastoma) in the upper part of the brain - Your tumor has been confirmed to have returned after prior treatment - You or your partner meets reproductive safety requirements - Your general health and brain function are adequate for the procedure **You may NOT be eligible if...** - You have a brain tumor in the brainstem or other inaccessible location - You have a very low performance status or significant neurological disability - You are pregnant or breastfeeding - You have serious active infections or uncontrolled medical conditions Talk to your doctor to see if this trial is right for you.